• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.抗病毒研究中百分比数据与对数数据的三维协同分析比较。
Antiviral Res. 2017 Sep;145:1-5. doi: 10.1016/j.antiviral.2017.06.022. Epub 2017 Jul 1.
2
Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice.西多福韦对小鼠致死性痘苗病毒呼吸道感染发病机制的影响。
Antiviral Res. 2001 Oct;52(1):55-62. doi: 10.1016/s0166-3542(01)00159-0.
3
Synergistic combination effect of cidofovir and idoxuridine on vaccinia virus replication.西多福韦与碘苷对痘苗病毒复制的协同联合效应。
Antivir Chem Chemother. 2006;17(2):53-8. doi: 10.1177/095632020601700201.
4
Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir.两种靶向B1R和G7L基因的小干扰RNA对痘苗病毒复制的抑制作用及其与西多福韦的协同组合
Antimicrob Agents Chemother. 2009 Jun;53(6):2579-88. doi: 10.1128/AAC.01626-08. Epub 2009 Mar 23.
5
Parapoxviruses are strongly inhibited in vitro by cidofovir.西多福韦在体外对副痘病毒有强烈抑制作用。
Antiviral Res. 2000 Dec;48(3):205-8. doi: 10.1016/s0166-3542(00)00130-3.
6
In vitro activity of cidofovir against the emerging Cantagalo virus and the smallpox vaccine strain IOC.西多福韦对新出现的坎塔加洛病毒和天花疫苗株IOC的体外活性。
Int J Antimicrob Agents. 2009 Jan;33(1):75-9. doi: 10.1016/j.ijantimicag.2008.07.015. Epub 2008 Sep 19.
7
[Biotechnological synthesis of ribavirin. Effect of ribavirin and its various combinations on the reproduction of Vaccinia virus].[利巴韦林的生物技术合成。利巴韦林及其各种组合对痘苗病毒繁殖的影响]
Bioorg Khim. 2004 Nov-Dec;30(6):613-20. doi: 10.1023/b:rubi.0000049772.18675.34.
8
Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice.西多福韦耐药痘苗病毒(WR株)在细胞培养和小鼠体内感染的特征与治疗
Antivir Chem Chemother. 2005;16(3):203-11. doi: 10.1177/095632020501600306.
9
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.ST-246与CMX001联合使用对抗正痘病毒的协同疗效。
Antimicrob Agents Chemother. 2007 Nov;51(11):4118-24. doi: 10.1128/AAC.00762-07. Epub 2007 Aug 27.
10
A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus.一种用于测定抗克里米亚-刚果出血热病毒抗病毒活性的简单检测方法。
Antiviral Res. 2004 Apr;62(1):21-5. doi: 10.1016/j.antiviral.2003.11.006.

引用本文的文献

1
Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection.在丁型肝炎病毒感染的肝脏嵌合小鼠模型中,用鼠源化托贝维巴特和埃莱西兰进行治疗是有效的。
JHEP Rep. 2025 Mar 22;7(6):101400. doi: 10.1016/j.jhepr.2025.101400. eCollection 2025 Jun.
2
Enhancing the Antiviral Potency of Nucleobases for Potential Broad-Spectrum Antiviral Therapies.增强核苷的抗病毒效力,用于潜在的广谱抗病毒疗法。
Viruses. 2021 Dec 14;13(12):2508. doi: 10.3390/v13122508.
3
ATR inhibition reverses the resistance of homologous recombination deficient MGMT/MMR cancer cells to temozolomide.共济失调毛细血管扩张症突变基因(ATR)抑制可逆转同源重组缺陷的甲基鸟嘌呤-DNA甲基转移酶(MGMT)/错配修复(MMR)癌细胞对替莫唑胺的耐药性。
Oncotarget. 2021 Oct 12;12(21):2114-2130. doi: 10.18632/oncotarget.28090.
4
Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.贝佐塞替布的脑分布:共济失调毛细血管扩张症和 Rad3 相关蛋白抑制剂治疗脑胶质母细胞瘤。
J Pharmacol Exp Ther. 2021 Dec;379(3):343-357. doi: 10.1124/jpet.121.000845. Epub 2021 Sep 23.
5
Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus.马拉韦罗与其他抗人巨细胞病毒药物联合的抗病毒活性。
Antiviral Res. 2018 Sep;157:128-133. doi: 10.1016/j.antiviral.2018.07.013. Epub 2018 Jul 21.

本文引用的文献

1
Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties.在针对具有不同细胞病变特性的RNA病毒进行的抗病毒检测中对细胞活力染料的评估。
J Virol Methods. 2017 Aug;246:51-57. doi: 10.1016/j.jviromet.2017.03.012. Epub 2017 Mar 27.
2
Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.JNJ63623872和奥司他韦对甲型H1N1pdm和H3N2流感病毒感染小鼠的活性。
Antiviral Res. 2016 Dec;136:45-50. doi: 10.1016/j.antiviral.2016.10.009. Epub 2016 Oct 19.
3
Enhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless mice.西多福韦联合牛痘免疫球蛋白治疗免疫抑制无毛小鼠进行性皮肤牛痘病毒感染的疗效增强
Antimicrob Agents Chemother. 2015 Jan;59(1):520-6. doi: 10.1128/AAC.04289-14. Epub 2014 Nov 10.
4
Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.开发CMX001(布林西多福韦)用于治疗由双链DNA病毒引起的严重疾病或病症。
Expert Rev Anti Infect Ther. 2014 Oct;12(10):1171-8. doi: 10.1586/14787210.2014.948847. Epub 2014 Aug 13.
5
In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.体外研究法匹拉韦与神经氨酸酶抑制剂联合用药对奥司他韦敏感和耐药的大流行性流感 A(H1N1)病毒的活性。
Arch Virol. 2014 Jun;159(6):1279-91. doi: 10.1007/s00705-013-1922-1. Epub 2013 Dec 6.
6
Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.进行性牛痘:病例描述及应用牛痘免疫球蛋白、ST-246 和 CMX001 的实验室指导治疗。
J Infect Dis. 2012 Nov;206(9):1372-85. doi: 10.1093/infdis/jis510. Epub 2012 Aug 16.
7
Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.法匹拉韦和帕拉米韦联合治疗甲型流感病毒/加利福尼亚/04/2009(H1N1)病毒感染的小鼠。
Antiviral Res. 2012 Apr;94(1):103-10. doi: 10.1016/j.antiviral.2012.03.001. Epub 2012 Mar 10.
8
Development of ST-246® for Treatment of Poxvirus Infections.ST-246® 的研发用于痘病毒感染的治疗。
Viruses. 2010 Nov;2(11):2409-2435. doi: 10.3390/v2112409. Epub 2010 Nov 3.
9
CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections.CMX001 增强阿昔洛韦在单纯疱疹病毒感染中的疗效。
Antimicrob Agents Chemother. 2011 Oct;55(10):4728-34. doi: 10.1128/AAC.00545-11. Epub 2011 Jul 25.
10
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.环丙沙星抑制人巨细胞病毒 UL97 激酶的正常功能。
Antimicrob Agents Chemother. 2011 Oct;55(10):4682-91. doi: 10.1128/AAC.00571-11. Epub 2011 Jul 25.

抗病毒研究中百分比数据与对数数据的三维协同分析比较。

Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.

作者信息

Smee Donald F, Prichard Mark N

机构信息

Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, 84322-5600, USA.

Department of Pediatrics, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, 35233-1711, USA.

出版信息

Antiviral Res. 2017 Sep;145:1-5. doi: 10.1016/j.antiviral.2017.06.022. Epub 2017 Jul 1.

DOI:10.1016/j.antiviral.2017.06.022
PMID:28676302
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5575975/
Abstract

Cell culture antiviral experiments were conducted in order to understand the relationship between percentage data generated by plaque reduction (PR) and logarithmic data derived by virus yield reduction (VYR) assays, using three-dimensional MacSynergy II software. The relationship between percentage and logarithmic data has not been investigated previously. Interpretation of drug-drug interactions is based on a Volume of Synergy (VS) calculation, which can be positive (synergy), negative (antagonistic), or neutral (no or minimal interaction). Interactions of two known inhibitors of vaccinia virus replication, cidofovir and 6-azauridine, used in combination by PR assay yielded a VS value of 265, indicative of strong synergy. By VYR, the VS value was only 37, or weak synergy using the same criterion, even though profound log reductions in virus titer occurred at multiple drug combinations. These results confirm that the differences in VS values is dependent of the measurement scale, and not that the degree of synergy differed between the assays. We propose that for logarithmic data, the calculated VS values will be lower for significant synergy and antagonism and that volumes of >10 μMlog PFU/ml (or other units such as μMlog genomic equivalents/ml or μMlog copies/ml) and <-10 μMlog PFU/ml are likely to be indicative of strong synergy and strong antagonism, respectively. Data presented here show that the interaction of cidofovir and 6-azauridine was strongly synergistic in vitro.

摘要

为了理解蚀斑减少(PR)产生的百分比数据与病毒产量减少(VYR)试验得出的对数数据之间的关系,使用三维MacSynergy II软件进行了细胞培养抗病毒实验。百分比数据和对数数据之间的关系此前尚未得到研究。药物相互作用的解释基于协同体积(VS)计算,其可以为正(协同)、负(拮抗)或中性(无或最小相互作用)。通过PR试验联合使用的两种已知痘苗病毒复制抑制剂西多福韦和6-氮杂尿苷的相互作用产生了265的VS值,表明有强协同作用。通过VYR试验,即使在多种药物组合下病毒滴度出现了显著的对数降低,VS值仅为37,按照相同标准为弱协同作用。这些结果证实VS值的差异取决于测量尺度,而非两种试验之间协同程度不同。我们提出,对于对数数据,显著协同和拮抗作用的计算VS值会更低,且大于10 μMlog PFU/ml(或其他单位,如μMlog基因组当量/ml或μMlog拷贝/ml)和小于-10 μMlog PFU/ml的体积可能分别表明有强协同作用和强拮抗作用。此处呈现的数据表明西多福韦和6-氮杂尿苷在体外有强烈的协同作用。